To delineate the potential of MCL1 to limit the clinical activity of chemotherapy such as doxorubicin or oxaliplatin, we evaluated the expression of MCL1 and the related family members Bcl-2 and Bcl-xL in a large panel of CRC tumor biopsies (n = 133) by IHC. This evidence concerns the gene BCL2L1 and neoplasm.